Earnings summaries and quarterly performance for MEDIFAST.
Executive leadership at MEDIFAST.
Daniel Chard
Detailed
Chief Executive Officer
CEO
AT
Anthony Tyree
Detailed
Chief Business Operations Officer
CG
Claudia Greninger
Detailed
Chief Human Resources Officer
JM
James Maloney
Detailed
Chief Financial Officer
JG
Jason Groves
Detailed
Chief Legal Officer & Corporate Secretary
JM
Jonathan MacKenzie
Detailed
Chief Accounting Officer
NJ
Nicholas Johnson
Detailed
Chief Field Operations Officer
Board of directors at MEDIFAST.
Research analysts who have asked questions during MEDIFAST earnings calls.
LB
Linda Bolton-Weiser
D.A. Davidson & Co.
3 questions for MED
Also covers: CLX, ELF, FLWS +14 more
Douglas Lane
Water Tower Research
2 questions for MED
Also covers: AOUT, BBW, BSET +8 more
James Salera
Stephens Inc.
2 questions for MED
Also covers: BRBR, CAKE, CELH +20 more
Jim Salera
Stephens Inc.
2 questions for MED
Also covers: BRBR, CAKE, CELH +21 more
Recent press releases and 8-K filings for MED.
Medifast Announces Q3 2025 Results and Q4 2025 Guidance
MED
Earnings
Guidance Update
Demand Weakening
- Medifast reported Q3 2025 revenue of $89 million, an operating loss of ($4.1 million), and a loss per share of ($0.21). The gross profit margin was 69.5%, representing a 590 basis point decline compared to Q3 2024.
- The company maintained a strong financial position, being debt-free with $174 million in cash and investments as of September 30, 2025, which is a 2% increase from the prior year period.
- Coach productivity trends stabilized, with revenue per active earning coach declining 2% year-over-year and 1% quarter-over-quarter, and the company reported 19,500 active earning coaches.
- Medifast is strategically transforming from a weight loss company to a metabolic health leader, introducing "Metabolic Synchronization" and planning a new product line launch in 2026.
- For Q4 2025, Medifast provided guidance anticipating revenue between $65 million and $80 million and a loss per share between ($0.70) and ($1.25).
Nov 3, 2025, 9:30 PM
Medifast Reports Q3 2025 Financial Results and Strategic Shift to Metabolic Health
MED
Earnings
Guidance Update
Demand Weakening
- Medifast reported Q3 2025 revenue of $89.4 million, a 36.2% decrease compared to the prior year, and a net loss of $2.3 million, resulting in a loss of $0.21 per diluted share.
- The company ended Q3 2025 with approximately 19,500 active earning OPTAVIA coaches, a 35% decrease from Q3 2024, with average revenue per coach at $4,585, down 1.9% year-over-year.
- Medifast is strategically evolving to become a leader in metabolic health, with plans to launch significant product innovations next year that will replace the current Essential product line.
- For Q4 2025, Medifast anticipates revenue to range from $65 million to $80 million and a loss per share between $0.70 and $1.25.
- The company maintains a strong financial position with $173.5 million in cash, cash equivalents, and investments and no interest-bearing debt as of September 30, 2025.
Nov 3, 2025, 9:30 PM
Medifast Announces Third Quarter 2025 Financial Results
MED
Earnings
Guidance Update
Demand Weakening
- Medifast reported third quarter 2025 revenue of $89.4 million, a 36.2% decrease from the third quarter of 2024.
- The company experienced a net loss of $2.3 million, or $0.21 loss per diluted share, for Q3 2025, compared to net income in the prior year period.
- The number of active earning OPTAVIA coaches decreased 35.0% to 19,500 in Q3 2025, primarily due to client acquisition challenges.
- Medifast maintained a strong balance sheet with $173.5 million in cash, cash equivalents, and investment securities and no debt as of September 30, 2025.
- For the fourth quarter of 2025, the company expects revenue to be in the range of $65 million to $80 million and diluted loss per share to be in the range of $0.70 to $1.25.
Nov 3, 2025, 9:15 PM
Medifast Announces Third Quarter 2025 Financial Results
MED
Earnings
Guidance Update
Demand Weakening
- Medifast reported Q3 2025 revenue of $89.4 million, a 36.2% decrease from the prior year, resulting in a net loss of $2.3 million or $0.21 loss per diluted share.
- The decline was primarily driven by a 35.0% decrease in active earning OPTAVIA coaches to 19,500, attributed to challenges with client acquisition due to the growing acceptance of GLP-1 medications for weight loss.
- The company maintains a strong balance sheet with $173.5 million in cash, cash equivalents, and investment securities and no debt as of September 30, 2025.
- For Q4 2025, Medifast expects revenue to be in the range of $65 million to $80 million and diluted loss per share to be in the range of $0.70 to $1.25.
Nov 3, 2025, 9:05 PM
Quarterly earnings call transcripts for MEDIFAST.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more